ChrysCapital to bet big on branded healthcare in India, says managing director Raghav Ramdev

livemint.com:

₹193 crore. Also read: ChrysCapital invests $100 million in eyecare chain Centre for Sight The firm has had tremendous success in its pharmaceuticals portfolio, having booked profits on investments in firms such as Torrent Pharma, Curatio Healthcare, GVK Biosciences, Cadila Healthcare and IPCA Laboratories. Its pharma portfolio is overseen by Partner Sanjiv Kaul, a former Ranbaxy Laboratories executive.

The firm is also invested in companies such as Mankind Pharma, Eris LifeSciences and Intas Laboratories. “Historically, we had done more pharma investments – that’s where we have had a lot of success. However, in the past three to four years, coming out of covid, healthcare itself has become a little more organised with insurance penetration going up and people becoming more choosy about their healthcare service provider," Ramdev said.

This has resulted in a re-rating of the sector, he added, explaining the firm's recent interest. Also read: Sure, insure people, but public healthcare for all is a must for Viksit Bharat ChrysCapital expects to evaluate deals across single-speciality and multi-speciality hospital chains in addition to healthcare delivery services such as diagnostics, medical devices, and contract development and manufacturing organisations (CDMOs) in the broader healthcare segment, he said. In single-speciality, ChrysCapital is looking at segments such as birthing, maternity, oncology, and opthalmology which have significant headroom for growth.